Zepbound
-
healthUS Prescription Drug Spending on Track to Exceed $1 Trillion, Fueled by GLP-1s
U.S. drug spending hit $915B in 2025, set to top $1T in 2026, driven by GLP-1 weight-loss drug demand. Eli Lilly and Novo Nordisk dominate the market.
-
healthMedicare Delays GLP-1 Weight-Loss Drug Program Amid Insurer Concerns
Medicare will offer GLP-1 weight-loss drugs via a temporary bridge program, delaying a new initiative due to insurer hesitations. Permanent integration remains uncertain.
-
healthNew Study Reveals Unreported Side Effects of Popular Weight-Loss Drugs
A University of Pennsylvania study analyzing Reddit posts uncovers potential new side effects of GLP-1 agonists like Ozempic and Mounjaro, beyond common gastrointestinal issues.
-
healthFDA Approves First Oral GLP-1 Weight-Loss Pill Foundayo
Foundayo is the latest once-daily pill approved for weight loss, offering flexibility without food or water restrictions.
-
healthDrug Combination Shows 35% Greater Weight Loss in Post-Menopausal Women
Mayo Clinic study reveals tirzepatide combined with hormone therapy delivers superior weight loss results for women over 50.
-
healthStopping GLP-1 Drugs Erases Heart Benefits Fast, Study Warns
New research shows cardiovascular protection from Ozempic and similar drugs vanishes within months of stopping - with lasting damage.
-
healthPrice Wars Reshape US Weight-Loss Drug Market
Eli Lilly and rivals slash prices amid fierce competition, pushing direct-to-consumer models while millions still lack insurance coverage.
-
techRoche Deploys 3,500 Nvidia Blackwell GPUs for Drug Discovery
Roche accelerates pharmaceutical R&D with 3,500 Nvidia Blackwell GPUs, targeting obesity drugs and challenging Eli Lilly's market dominance.